The prospective REDUCE-GAD study reports that higher serum neurofilament-light chain (NfL) levels are associated with the presence of contrast-enhancing (CE) lesions, which may enable clinicians to forego contrast agents for follow-up MRIs (Schaefer et al. Eur J Neurol 2023;30:2393-2400). Read More
Latest News
CLINICAL CASES IN MS – A DIAGNOSTIC DILEMMA
July 26, 2023Click here to watch Dr. Daniel Selchen discuss the case and the responses to the survey.
Ken, a 53-year-old man, was initially seen in 2017 following onset of painful spasms in R leg and probable clonus while driving his car. He developed R leg weakness and band-like discomfort across his chest. He was worked up for stroke and cardiac issues and all investigations were negative. He had a prior history of asthma with nasal polyps and NSAID-associated dyspnea.
Revised recommendations on the differential diagnosis of MS
July 25, 2023The Multiple Sclerosis Differential Diagnosis Consortium has published consensus recommendations on the differential diagnosis of multiple sclerosis (Solomon et al. Lancet Neurol 2023;22:750-768). This version updates recommendations published 15 years ago (Miller et al. Mult Scler 2008;14:1157-1174). Read More
Lower risk of Gd+ lesions, new T2 lesions in older MS patients
July 18, 2023Relapse-onset MS patients have a substantially reduced risk of contrast-enhancing lesions or new T2 lesions after they reach age 50 years, according to a longitudinal analysis of the Amsterdam MS cohort study (Coerver et al. Eur J Neurol 2023;30:2385-2392). Read More